PD1-vaxx and B-vaxx: Kaumaya article in Brit ash Journal of Cancer

Morning all

I was about to go out and get myself a life when I came across a reference to a new article by Prof Kaumaya and an associate, apparently just published in the British Journal of Cancer:

"First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations"

This looks like it would be extremely interesting - but it's behind a pay wall. All we can see is the Summary:

"We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx)." Source: https://www.nature.com/articles/s41416-021-01342-9#Abs1

Hey Team Imugene - any chance of getting this article published on the IMU website? I guess I could always pay the $8.99 and get it myself....

Maybe after a day out in the sun!!!!

Cheers

Dave